BioCentury
ARTICLE | Regulation

New nasal spray option for dry eye as Oyster Point wins FDA nod

Oyster Point’s Tyrvaya offers dosing advantage over artificial tears

October 18, 2021 11:00 AM UTC
Updated on Oct 18, 2021 at 9:24 PM UTC

FDA’s approval of Oyster Point’s Tyrvaya will afford U.S. patients their first nasal spray option to treat signs and symptoms of dry eye.

Along with the novel method of delivery, Tyrvaya varenicline (OC-01) from Oyster Point Pharma Inc. (NASDAQ:OYST) offers patients a dosing advantage over the first-line standard of care, which is over-the-counter artificial tears. Those treatments are saline-based, do not contain the complex mixture of bioactive molecules present in natural tears, and may have to be re-applied as frequently as every 15 minutes...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article